Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe access-denied screen is replaced by the full clinical-trial record, including study details, eligibility criteria, locations, outcomes, and supporting documents.SummaryDifference100%

- Check19 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden error instead of study information.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” It appears above the page’s 403 error message.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer identifies the site as revision v3.7.1 instead of v3.7.0. The study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedA 403 Forbidden error now displays on the study details page, replacing the content that previously showed trial information. This prevents users from viewing enrollment details, eligibility criteria, and contact information.SummaryDifference0.5%

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.